Association of investigated SNPs with toxic events
| Polymorphism . | ABCB1 c.2677 G>T/A . | NCF4 c.368G>A . | GSTP1 c.313.A>G . | CRBN rs1705814 T>C . |
|---|---|---|---|---|
| Hematological toxicity during the induction phase | HoPOL:OR, 0.39 (CI, 0.15-0.88); P = .033 | HoPOL/HePOL: OR, 0.56 (CI, 0.34-0.92); P = .024 | HoPOL:OR, 0.35 (CI, 0.15-0.79); P = .014 | |
| Combined effect | HoWT: OR, 2.26 (CI, 1.09-4.83); P = .031 | |||
| Infective toxicity | HoPOL: OR, 0.53 (CI, 0.30-0.95) P = .030 | HoPOL: OR, 0.39 (CI, 0.22-0.68); P = .001 | ||
| Lenalidomide dose reduction | HoPOL: OR, 3.24 (CI, 1.69-6.21); P = .013 | |||
| Polymorphism . | ABCB1 c.2677 G>T/A . | NCF4 c.368G>A . | GSTP1 c.313.A>G . | CRBN rs1705814 T>C . |
|---|---|---|---|---|
| Hematological toxicity during the induction phase | HoPOL:OR, 0.39 (CI, 0.15-0.88); P = .033 | HoPOL/HePOL: OR, 0.56 (CI, 0.34-0.92); P = .024 | HoPOL:OR, 0.35 (CI, 0.15-0.79); P = .014 | |
| Combined effect | HoWT: OR, 2.26 (CI, 1.09-4.83); P = .031 | |||
| Infective toxicity | HoPOL: OR, 0.53 (CI, 0.30-0.95) P = .030 | HoPOL: OR, 0.39 (CI, 0.22-0.68); P = .001 | ||
| Lenalidomide dose reduction | HoPOL: OR, 3.24 (CI, 1.69-6.21); P = .013 | |||